Difficile Infection

Clostridium difficile is a gram positive, spore forming anaerobic bacillus, which may or may not carry the genes for toxin A-B production (Nipa, 2010). These two types of protein exotoxins produced by the Clostridium difficile bacillus, toxin A and toxin B, can have an infectious form and a non-active, non-infectious form (Grossman, 2010). The infectious form can survive for a short duration of time in the environment. The spores can survive for a longer period of time in the environment and are not infectious unless and until they are ingested or are transformed into an infectious state (Nipa, 2010).

This paper will mainly explain what Clostridium difficile is, its causal agent, epidemiology, ways of transmission, some clinical features, diagnoses and how to test for the bacterium, treatment, prognosis, and preventative measures. There are treatments available for this

Clostridium difficile is a Gram-positive, spore-forming, rod-shaped bacillus that is renowned for being the leading cause of hospital-acquired diarrhea in adult patients. C. difficile is present as normal intestinal flora within 3% to 5% of healthy people2, while its spores are ubiquitous in the environment, especially in hospital settings. It grows at an optimal temperature and pH of 37ºC and 6.5–7.5 respectively.1 It is an obligate anaerobic as it thrives in the absence of oxygen. It is highly motile with the presence of peritrichous flagella, which are evenly spread out along its surface. As briefly mentioned above, this evolving pathogen produces endospores. The bacterium produces dormant spores, which are extremely hardy and resistant to antibiotics, the host’s innate immune system, and once shed into the environment through the host’s feces, they are resistant to unfavorable aerobic conditions3 as well as several types of bleach-free disinfectants, which are commonly used in hospitals.3 The spores will germinate under the favorable conditions of the intestinal tract, resulting in the multiplication of vegetative cells, colonizing in the gastrointestinal tract. The vegetative cells release two powerful exotoxins upon adherence to the epithelial cells of the GI tract. Pathogenic strains of C. difficile produce two exotoxins: toxin A and toxin B. Toxin A is an enterotoxin that causes fluid excretion, resulting in fluid accumulation and watery diarrhea. Toxin B is a potent

Clostridium Difficile (C-Diff) is considered one of the most common infections a patient can acquire within their hospital stay. It is estimated that C-Diff is responsible for 337,000 infections and 14,000 deaths a year (Centers for Disease Control and Prevention, 2012). Working in the emergency department (ED), I have witness first hand how debilitating this gastrointestinal infection can be. Patients are admitted to the ED for having severe watery diarrhea, abdominal pain, and fever. Elderly patients are at increase risk for sepsis and dehydration related to recurrent infections. Appropriate management and education of C-Diff is optimal for patient survival and decrease contamination across lifespan.

Many Americans die each year from complications connected to Clostridium difficile. It can ill a significant number of individuals as well as animals. The Clostridium difficile infection is the result of poor hygiene, misuse, overuse of antibiotics and an aging population. In this paper I will be discussing the following topics, what clostridium difficile means, what it causes, signs and symptoms, complications, treatment and the prevention.

Clostridium difficile involves a gram-positive spore-forming bacterium, which is a normal element of the colon flora in people. The Clostridium difficile can cause antibiotic-associated diarrhea when the competing bacteria in the gut flora are all killed by antibiotic treatment. The Clostridium difficile infection is one of the serious healthcare-related infection and also a rising health care problem. In the early 1970s, the Clostridium difficile has been known to have the ability to cause pseudomembranous colitis. As stated, the infection is the most cause of nosocomial infectious diarrhea (Aktories & Wilkins, 2000). Individuals that are colonized with clostridium difficile serve as the reservoir for infection and this is by contaminating the environment with spores of such bacteria. This will lead to the spread of the organism on the health care worker’s hands or even through the use of medical equipment. In this paper, we are going to focus on the effective prevention strategies for clostridium difficile. What are the effective prevention strategies for clostridium difficile?

The healthcare professional can expect to encounter various conditions within their scope of experience. Clostridium difficile represents one of the most common and challenging nosocomial infections that can cause life-threatening complications such as hypervolemia, sepsis, pain, and peritonitis (Grossman and Mager 155). The recognition, diagnosis, treatment and inhibition of transmission of this bacterium are imperative in order to limit infection and prevent death.

Ample literature has been published to elucidate the pervasive nature of Clostridium difficile and its relationship with inadequate health-care practices. Clostridium difficile-associated disease: New challenges from an established pathogen by Sunshine and McDonald, published in the Cleveland Clinic Journal of Medicine discusses the concern over Clostridium difficile. It includes a case report involving infection caused by the bacterium and important guidelines for prevention and treatment associated with the bacterium.

C. difficile is a spore-forming and strict anaerobe gram-positive bacillus [4], capable of excreting pathogenic toxins, as discussed below [3]. This spore forming ability is a method of bacterial persistence within the human body. C. difficile is able to resist and survive a variable environment when various other microbes cannot. Three important factors affecting the risk of CDI include the use of antibiotics, length of hospital-environment exposure and age [1]. The use of broad range antibiotics affects the composition and lively-hood of normal

Clostridium difficile is a gram-positive bacterium which causes diarrhoea. It also known as antibiotic associated diarrhoea and also pseudomembranous colitis. The bacterium secretes large protein toxin that also causes toxic mega colon. Clostridium difficile is caused by when a person is given one of the following antibiotics: Cephalosporin, penicillin (particularly Ampicillin or Amoxicillin), Clindamycin and Fluoroquinolone. The antibiotic will remove the entire normal flora in the colon. The lack of normal flora will make the person vulnerable to infection especially to Clostridium difficile because Clostridium difficile produces hardy spores

Clostridium difficile (C-diff) is a bacterium of the intestine that usually develops after the start of antibiotics in at risk patients. C-diff causes inflammation of the intestine by irritating the lining of the intestinal wall. C-diff can cause many symptoms with lose stool multiple times throughout the day for more than two days being the most common. Severe infections can lead to hemodynamic changes in the body that could lead to hospitalization and/or surgery. The spores from C-diff can be passed on from months if an affected surface is not properly cleaned after being exposed to the bacteria. Proper hand washing must take place to avoid ingestion of the bacteria. C-diff is a form

Clostridium Difficile, or C. diff, is a common occurrence in hospitals. But how does one know that they are in fact dealing with a patient with C. diff and not just diarrhea? It all lies in the symptoms. C. diff diarrhea has a distinct odor. The patient also feels a constant urgency, a need to always go to the restroom. The stool contains mucous. Beyond that, most patients will present with a low grade fever, mild leukocytosis, hyperactive bowel sounds, and mild abdominal tenderness. (Headly, 461)

Health care acquired infection (HCAI) exerts a massive impact on the health care services delivery and improvement of its quality. It has been reported among leading culprits of prolonged admission, increased mortality, long-term disability and complications, emergence of multidrug resistant organism (MDRO), and they are costing healthcare services a great deal of money.(1, 2) At a given time, occurrence of HCAI is 15.5 per 100 patients in developing countries and 5 to 12 per 100 patients in developed countries. It is estimated that approximately 1 out of every 20 hospitalized patients will contract an HCAI.(3) In a summery and updating reviews done in 2014 by WHO concluded that more than a quarter of the MERS-cov infections have been

The purpose of this paper is to develop a summary that you could use within an evidence-based practice (EBP) committee or related venue to share with your colleagues. In this case, this summary will be focused on guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections (Surawicz et al., 2013). This paper will discuss the scope and purpose of the clinical practice guideline, examine stakeholder involvement, review rigor of development, analyze recommendations for practice, and concluding with implementation of clinical practice guidelines regarding the issue of infection

Most of the public have heard of broad-spectrum drugs, especially in terms of antibiotic resistance, because they fight a wide range of bacteria but also kills normal flora in the gut (Haddox, 2013). The loss of this gut flora can lead to an abnormal growth of harmful bacteria such as clostridium difficile (C-Diff). The four “C” antibiotics that have a high risk for patient to develop C-diff are clindamycin, cephalosporins, coamoxiclav, and ciprofloxacin (Haddox, 2013). These antibiotics have the highest risk of leading to C-diff development, however all antibiotics increase a patient’s likelihood of a C-diff infection. This effect can last up to 12 weeks post antibiotic administration (Haddox, 2013).